The world's most advanced AI skin cancer pathways

Skin Analytics supports NHS dermatology teams by creating patient pathways that leverage our AI as a Medical Device (AIaMD), DERM, to help triage patients to the right place at the right time.

derm-video
Play Video about derm-video

Cancer Wait Times for dermatology are challenging

Dermatologists work hard to review hundreds of thousands of patients placed on the urgent suspected skin cancer pathways annually; however with 1 in 4 consultant posts unfilled [1] and trainee numbers not rising [2], demand continues to outweigh capacity. In 2023, >180,000 patients waited more than 28 days after urgent cancer referral for their diagnosis [3]. Diagnostic delays of 2 weeks or more can lead to a 20% decrease in 5-year-survival rates [4]. This current scenario is unsafe and unsustainable, but preventable.

With no easy way to suddenly increase the number of dermatologists, AIaMD can offer an alternative way to extend dermatology capacity, address demand, speed up current diagnostic pathways and improve patient outcomes.

[1] https://gettingitrightfirsttime.co.uk/wp-content/uploads/2021/09/DermatologyReport-Sept21o.pdf
[2] https://medical.hee.nhs.uk/medical-training-recruitment/medical-specialty-training/competition-ratios
[3] https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
[4] Pacifico M, Pearl R, Grover R.
The UK Government Two-Week Rule and its Impact on Melanoma Prognosis: An Evidence-Based Study.
The Annals of The Royal College of Surgeons of England. 2007;89(6):609-615.

Our typical pathway

ai-solutions-pathway-step-1

1. GP referral

GP refers to secondary care on the urgent suspected skin cancer pathway as normal.

2. Image capture

Patients’ first appointments are at an imaging clinic, where consent, medical history, context and dermoscopic images are captured.

3. AI assessment

DERM assesses the dermoscopic images of lesions only.

4. Next steps

Based on the outcome of the AI assessment, the case will be directed to the right level of care.

Management outcomes

ai-solutions-low-risk-lesions

BENIGN

Patients are sent an outcome letter confirming the results and are discharged from the urgent suspected skin cancer pathway.

ai-solutions-high-risk-lesions

PREMALIGNANT/ MALIGNANT

A trust dermatologist will review the case virtually and decide on a management outcome which will then be communicated to the patient.

Over 120,000 NHS patients assessed

Proven experience with strong outcomes for our partners

At the end of Q2 2024, Skin Analytics had assessed over 120,000 NHS patients for suspicion of skin cancer. Our performance reporting shows our system consistently performs at a level comparable to specialists while reducing the number of urgent suspected cancer referrals dermatology teams need to review face to face.

Find out more

If you would like to know more about how Skin Analytics can help you and your dermatology team deliver best in class dermatology, get in touch.

Subscribe to our news updates

We won't spam
you, we promise.